These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 19894051)

  • 1. A phase I trial of UCN-01 and prednisone in patients with refractory solid tumors and lymphomas.
    Kummar S; Gutierrez ME; Gardner ER; Figg WD; Melillo G; Dancey J; Sausville EA; Conley BA; Murgo AJ; Doroshow JH
    Cancer Chemother Pharmacol; 2010 Jan; 65(2):383-9. PubMed ID: 19894051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors.
    Jimeno A; Rudek MA; Purcell T; Laheru DA; Messersmith WA; Dancey J; Carducci MA; Baker SD; Hidalgo M; Donehower RC
    Cancer Chemother Pharmacol; 2008 Mar; 61(3):423-33. PubMed ID: 17429623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies.
    Fracasso PM; Williams KJ; Chen RC; Picus J; Ma CX; Ellis MJ; Tan BR; Pluard TJ; Adkins DR; Naughton MJ; Rader JS; Arquette MA; Fleshman JW; Creekmore AN; Goodner SA; Wright LP; Guo Z; Ryan CE; Tao Y; Soares EM; Cai SR; Lin L; Dancey J; Rudek MA; McLeod HL; Piwnica-Worms H
    Cancer Chemother Pharmacol; 2011 Jun; 67(6):1225-37. PubMed ID: 20694727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I trial of UCN-01 in combination with topotecan in patients with advanced solid cancers: a Princess Margaret Hospital Phase II Consortium study.
    Hotte SJ; Oza A; Winquist EW; Moore M; Chen EX; Brown S; Pond GR; Dancey JE; Hirte HW
    Ann Oncol; 2006 Feb; 17(2):334-40. PubMed ID: 16284058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with Fluorouracil in patients with advanced solid tumors.
    Kortmansky J; Shah MA; Kaubisch A; Weyerbacher A; Yi S; Tong W; Sowers R; Gonen M; O'reilly E; Kemeny N; Ilson DI; Saltz LB; Maki RG; Kelsen DP; Schwartz GK
    J Clin Oncol; 2005 Mar; 23(9):1875-84. PubMed ID: 15699481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms.
    Sausville EA; Arbuck SG; Messmann R; Headlee D; Bauer KS; Lush RM; Murgo A; Figg WD; Lahusen T; Jaken S; Jing X; Roberge M; Fuse E; Kuwabara T; Senderowicz AM
    J Clin Oncol; 2001 Apr; 19(8):2319-33. PubMed ID: 11304786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of cell cycle progression in human tumors: a pharmacokinetic and tumor molecular pharmacodynamic study of cisplatin plus the Chk1 inhibitor UCN-01 (NSC 638850).
    Perez RP; Lewis LD; Beelen AP; Olszanski AJ; Johnston N; Rhodes CH; Beaulieu B; Ernstoff MS; Eastman A
    Clin Cancer Res; 2006 Dec; 12(23):7079-85. PubMed ID: 17145831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cyclin-dependent kinase inhibitor UCN-01 plus cisplatin in advanced solid tumors: a California cancer consortium phase I pharmacokinetic and molecular correlative trial.
    Lara PN; Mack PC; Synold T; Frankel P; Longmate J; Gumerlock PH; Doroshow JH; Gandara DR
    Clin Cancer Res; 2005 Jun; 11(12):4444-50. PubMed ID: 15958629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I study of UCN-01 and perifosine in patients with relapsed and refractory acute leukemias and high-risk myelodysplastic syndrome.
    Gojo I; Perl A; Luger S; Baer MR; Norsworthy KJ; Bauer KS; Tidwell M; Fleckinger S; Carroll M; Sausville EA
    Invest New Drugs; 2013 Oct; 31(5):1217-27. PubMed ID: 23443507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I and pharmacokinetic study of 7-hydroxystaurosporine and carboplatin in advanced solid tumors.
    Edelman MJ; Bauer KS; Wu S; Smith R; Bisacia S; Dancey J
    Clin Cancer Res; 2007 May; 13(9):2667-74. PubMed ID: 17473198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel direct and indirect cyclin-dependent kinase modulators for the prevention and treatment of human neoplasms.
    Senderowicz AM
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S61-73. PubMed ID: 12819936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I trial of continuous infusion 9-aminocamptothecin in patients with advanced solid tumors: 21-day infusion is an active well-tolerated regimen.
    Sewak S; Sorich J; O'Leary J
    Anticancer Drugs; 2006 Jun; 17(5):571-9. PubMed ID: 16702815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II study of cell cycle inhibitor UCN-01 in patients with metastatic melanoma: a California Cancer Consortium trial.
    Li T; Christensen SD; Frankel PH; Margolin KA; Agarwala SS; Luu T; Mack PC; Lara PN; Gandara DR
    Invest New Drugs; 2012 Apr; 30(2):741-8. PubMed ID: 20967484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase-I dose escalation and sequencing study of docetaxel and continuous infusion topotecan in patients with advanced malignancies.
    Posey JA; Wang H; Hamilton J; Delgrosso A; Zhang R; Freda T; Zamboni WC
    Cancer Chemother Pharmacol; 2005 Aug; 56(2):182-8. PubMed ID: 15838660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I trial of daily oral 4'- N -benzoyl-staurosporine in combination with protracted continuous infusion 5-fluorouracil in patients with advanced solid malignancies.
    Eder JP; Garcia-Carbonero R; Clark JW; Supko JG; Puchalski TA; Ryan DP; Deluca P; Wozniak A; Campbell A; Rothermel J; LoRusso P
    Invest New Drugs; 2004 Apr; 22(2):139-50. PubMed ID: 14739662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
    Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
    Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies.
    Paik PK; Rudin CM; Brown A; Rizvi NA; Takebe N; Travis W; James L; Ginsberg MS; Juergens R; Markus S; Tyson L; Subzwari S; Kris MG; Krug LM
    Cancer Chemother Pharmacol; 2010 Nov; 66(6):1079-85. PubMed ID: 20165849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I study of capecitabine in combination with cisplatin and irinotecan in patients with advanced solid malignancies.
    Sayar H; Shen Z; Lee SJ; Royce M; Rabinowitz I; Lee F; Smith H; Eberhardt S; Maestas A; Lu H; Verschraegen C
    Invest New Drugs; 2009 Apr; 27(2):153-8. PubMed ID: 18773144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I study of docetaxel and topotecan in patients with solid tumors.
    Tkaczuk KH; Zamboni WC; Tait NS; Meisenberg BR; Doyle LA; Edelman MJ; Hausner PF; Egorin MJ; Van Echo DA
    Cancer Chemother Pharmacol; 2000; 46(6):442-8. PubMed ID: 11138457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I Clinical Trial of the Wee1 Inhibitor Adavosertib (AZD1775) with Irinotecan in Children with Relapsed Solid Tumors: A COG Phase I Consortium Report (ADVL1312).
    Cole KA; Pal S; Kudgus RA; Ijaz H; Liu X; Minard CG; Pawel BR; Maris JM; Haas-Kogan DA; Voss SD; Berg SL; Reid JM; Fox E; Weigel BJ
    Clin Cancer Res; 2020 Mar; 26(6):1213-1219. PubMed ID: 31857431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.